SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

Zentalis reports updated DENALI trial results for azenosertib in platinum-resistant ovarian cancer, showing 6.3 months median duration of response. Updated median duration of response (mDOR) of 6. ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

This is event is part of the James M. and Cathleen D. Stone Distinguished Speaker Series. Maureen Dowd has been a New York Times columnist since 1995, winning a Pulitzer Prize in 1999 for her ...

Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

I’m an Opinion columnist at The New York Times. What I cover: I focus mostly on presidential politics, but I like to branch out and write about New York, Hollywood, Silicon Valley and ...

Maureen Dowd's new collection, "Notorious," features conversations with Kevin Costner, Uma Thurman, Paul Newman and other celebrities. (Jordan Strauss / Invision / AP; Evan Agostini / Invision ...

Maureen Dowd has been profiling the rich, famous and powerful for the New York Times since the 1980s. As she writes in her new collection, “Notorious,” “I’ve always been fascinated by how ...